| Market Capitalization (Millions $) |
16,905 |
| Shares
Outstanding (Millions) |
69 |
| Employees |
2,890 |
| Revenues (TTM) (Millions $) |
4,601 |
| Net Income (TTM) (Millions $) |
941 |
| Cash Flow (TTM) (Millions $) |
654 |
| Capital Exp. (TTM) (Millions $) |
230 |
Business Description
Jazz Pharmaceuticals Plc is a bio-pharmaceutical company that primarily focuses on developing and commercializing innovative treatments for various medical conditions, including sleep disorders, oncology, and neurology. It was founded in 2003 and is headquartered in Dublin, Ireland.
The company's portfolio includes several marketed products, such as:
1. Xyrem: It is an FDA-approved medication for the treatment of the rare sleep disorder called cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy.
2. Erwinaze: It is a medication used in the treatment of acute lymphoblastic leukemia (ALL) to convert asparagine to aspartic acid, thereby starving tumor cells of asparagine.
3. Defitelio: It is a drug that is used in the treatment of rare, life-threatening, and rapidly progressing liver and lung conditions associated with stem cell transplant.
Jazz Pharmaceuticals has several drugs that are currently in the clinical trial phase for treating other medical conditions like resistant depression, fibromyalgia, and Parkinson's disease.
The company's revenue is generated primarily from the sale of its products, which are marketed and sold in the United States, Europe, and other regions. In 2020, Jazz Pharmaceuticals reported total corporate revenue of $2.3 billion.
Jazz Pharmaceuticals has a diverse team of approximately 2,200 employees worldwide who work together to develop, manufacture, and market its products. The company is committed to adhering to high ethical standards and ensures compliance with all legal and regulatory requirements.
Jazz Pharmaceuticals has received many awards and accolades for its efforts in the field of bio-pharmaceuticals, including the Pharma Marketing Award for its patient-focused marketing campaign for Xyrem. It has also been listed among the "Fastest Growing Companies" in Ireland and the United States.
Overall, Jazz Pharmaceuticals is a leading player in the bio-pharmaceutical industry with a focus on developing innovative treatments for various medical conditions. Its commitment to research, development, and high ethical standards has contributed to its success and growth over the years.
Company Address: Fifth Floor, Waterloo Exchange, Dublin 4 0
Company Phone Number: 634-7800 Stock Exchange / Ticker: NASDAQ JAZZ
|
4.62% 
180.53 %